SCHEMBL30208191

SCHEMBL30208191

CC(C)(C)OC(=O)c1ccc(F)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.53
CES1 P23141 2/20 0.53
CHRNA1 P02708 1/20 0.49
CHRNG P07510 1/20 0.49
CHRNB1 P11230 1/20 0.49
CHRNB2 P17787 1/20 0.49
SLC6A2 P23975 1/20 0.49
CHRNB4 P30926 1/20 0.49
CHRNA3 P32297 1/20 0.49
CHRNA4 P43681 1/20 0.49
SLC6A3 Q01959 1/20 0.49
CHRND Q07001 1/20 0.49
PLA2G7 Q13093 1/20 0.47
GABRA1 P14867 1/20 0.47
GABRG2 P18507 1/20 0.47
GABRB3 P28472 1/20 0.47
GABRA3 P34903 1/20 0.47
GABRA2 P47869 1/20 0.47
RAB9A P51151 2/20 0.46
CA12 O43570 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4208340 1.00 CES2 (0.53) CES2CES1CHRNA1CHRNGCHRNB1
SCHEMBL31587898 0.86 CA12 (0.46) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL4816280 0.86 HDAC1 (0.53) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL3744003 0.86 CA9 (0.46) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL4024106 0.86 HTR7 (0.46) CES2CES1CHRNA1CHRNGCHRNB1
SCHEMBL23093930 0.84 ALOX15 (0.50) PLA2G7GABRA1GABRG2GABRB3GABRA3
SCHEMBL355461 0.84 HDAC1 (0.51) CES2CES1GABRA1GABRG2GABRB3
SCHEMBL17864531 0.84 CA12 (0.45) CES2CES1CHRNA1CHRNGCHRNB1
SCHEMBL29388368 0.84 CA12 (0.45) CES2CES1CHRNA1CHRNGCHRNB1
SCHEMBL4203797 0.84 MAPT (0.48) GABRA1GABRG2GABRB3GABRA3GABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577231-B2 Androgen receptor PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-03-17 US disclosed
US-20260001865-A1 ANDROGEN RECEPTOR PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-01-01 US disclosed
WO-2025061906-A1 ANDROGEN RECEPTOR PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-03-27 WO disclosed
EP-4114829-A1 MONOACYLGLYCEROL LIPASE INHIBITORS Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) 2023-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001865-A1 ANDROGEN RECEPTOR PROTACS AR, CRBN, PSMA3 CES2 2529/4885CES1 1771/4885CHRNA1 256/4885
US-12577231-B2 Androgen receptor PROTACS AR, CRBN, PSMA3 CES2 2529/4885CES1 1771/4885CHRNA1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.